News & Views
Experienced CEO to Lead Therapeutics Company
Jan 22 2021
Leeds-based LUNAC Therapeutics, focused on developing life-saving anticoagulants with minimal risk of bleeding, has appointed Carl Sterritt as Chief Executive Officer. With over 25 years of management and executive level experience in pharmaceutical research and business development Carl’s main focus has been on value creation and delivery for both large and small companies in the private and and public sectors, latterly as Founder and Chief Executive of Shield Therapeutics plc.
He is also co-Founder and Chairman of PharmaKrysto Ltd, developers of a new therapy for people with Cystinuria. He also led the European operations of United Therapies and Encysive Pharmaceuticals, developing and commercialising therapies for the treatment of pulmonary arterial hypertension.
"I am delighted to be appointed CEO of LUNAC at this important point in the Company’s journey. We have high quality IP licensed from one of the UK’s leading research-based academic institutions, the close support of the world-leading scientists who invented that IP and a very strong roster of supportive and committed shareholders. Having spent the last 10 years successfully creating and building Shield Therapeutics from an idea to a publicly-listed company, I look forward to bringing my full focus, entrepreneurialism and experience to bear for the benefit of LUNAC as we seek to move the Company forward apace.“
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Microbiology Society Annual Conference 2024
Apr 08 2024 Edinburgh 2024
Apr 09 2024 Munich, Germany
Apr 10 2024 Helsinki, Finland
Analytica Anacon India & IndiaLabExpo
Apr 15 2024 Mumbai, India
Apr 16 2024 Moscow, Russia